Skip to content

Replimune Group REPL Common Stock Shares Outstanding

Common Stock Shares Outstanding at other companies

Tango Therapeutics logo
Tango TherapeuticsTNGX
$313.61M
Immunovant, Inc. logo
Immunovant, Inc.IMVT
$117.2M-34.5%
ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX

Other financials

Income statement

See full
Operating income-$71.9M-8.9%
Net income-$70.9M-6.9%
EPS (diluted)-$0.77+2.5%

Balance sheet

See full
Cash & equivalents$124.7M-28.3%
Total debt$79.2M+0.5%
Total equity$210.5M-56.4%
Total assets$333.6M-44.7%

Cash flow

See full
Operating cash flow-$66.0M-30.1%
CapEx$135.0K-92.5%
Free cash flow-$66.1M-25.9%

Valuation

See full
Market cap$930.59M+28.6%
Enterprise value$885.15M+28.3%

Returns & leverage

See full
Return on equity-90.9%+362pp
Debt / equity0.4×+0.2×
Current ratio5.6×-5.8×

Where this comes from

Reported directly by Replimune Group in its filing.

Tagged under the XBRL concept us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue.

The official record: Replimune Group’s 10-Q, filed February 3, 2026, on SEC EDGAR. View the filing →

Ask your AI about Replimune Group's common stock shares outstanding.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Replimune Group's common stock shares outstanding?
Replimune Group (REPL) reported common stock shares outstanding of $12.76M in Q4 2025.
How has Replimune Group's common stock shares outstanding changed year-over-year?
Replimune Group's common stock shares outstanding decreased by 38.4% year-over-year, from $20.72M to $12.76M.
What is the long-term trend for Replimune Group's common stock shares outstanding?
Over 4 years (2021 to 2025), Replimune Group's common stock shares outstanding has grown at a -45.0% compound annual growth rate (CAGR), from $116.19M to $10.65M.
What does common stock shares outstanding mean?
This represents the total number of common shares held by all shareholders, including institutional investors and insiders. It serves as the denominator for calculating earnings per share and is a key indicator of potential equity dilution. Changes in this figure reflect share repurchases, new issuances, or conversion of convertible securities.